Excellent
Mostly Aligned
Patient Risk:
Low
Summary
All provided claims regarding generic naming and FDA-indicated uses for XYZAL (levocetirizine) are consistent with the supplied prescribing information excerpts; no contraindication, warning, dosing, or interaction claims were made.
Category Scores
Accurate Statements
Levocetirizine is the generic name (international nonproprietary name, INN) of the medicine.
The supplied label excerpt identifies the active ingredient as levocetirizine dihydrochloride under the drug XYZAL.
Levocetirizine is the active ingredient in many allergy products.
Supported insofar as the label excerpt establishes levocetirizine (dihydrochloride) as the active ingredient of XYZAL; the excerpt does not enumerate other products.
Levocetirizine is used for allergic rhinitis.
XYZAL is indicated for the relief of symptoms associated with perennial allergic rhinitis (Section 1.1).
Levocetirizine is used for chronic idiopathic urticaria.
XYZAL is indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 months of age and older (Section 1.2).
Unsupported Statements
Levocetirizine is the active ingredient in many allergy products.
The provided prescribing information excerpts only establish levocetirizine as the active ingredient of XYZAL and do not support the claim that it is in 'many' other allergy products.
Contradictions
Important Omissions
For the allergic rhinitis claim, the label specifies 'perennial allergic rhinitis' and includes an age range (children 6 months to 2 years) in the provided excerpt.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
Claims were limited to indication/generic-description statements; no dosing, contraindication, or safety-use guidance was provided or misrepresented.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
One claim ('active ingredient in many allergy products') is broader than what the provided label excerpts support.
Suggested Improvement
Limit such statements to what the label excerpt supports (e.g., that levocetirizine is the active ingredient in XYZAL) and, for rhinitis, specify 'perennial allergic rhinitis' as labeled in the provided excerpt.